WhiteLab Genomics Raises $26M Series B Led by AVP

WhiteLab Genomics, the Paris-headquartered TechBio company, has raised a $26 million Series B round led by AVP (Atlantic Vantage Point). The round was disclosed on October 5, 2026.

What WhiteLab Genomics Does

WhiteLab Genomics runs an AI platform that performs in-silico simulations for the design of gene, cell, RNA and DNA therapies. Its scope spans from target discovery to vector and payload design and genotoxicity assessment.

Rather than relying on trial-and-error wet-lab testing, the company's predictive models rank candidate therapy designs before experiments begin. That positioning places WhiteLab Genomics upstream of the bench, where design decisions shape which candidates ever reach testing.

Customers and Footprint

WhiteLab Genomics serves biotech and pharma customers in Europe and the US, with additional sites in North America beyond its Paris headquarters.

Company Background

Founded: 2019
Founders: David Del Bourgo and Julien Cottineau
Accelerator: Y Combinator Winter 2022 graduate
Prior round: $10M Series A co-led by Debiopharm Innovation Fund alongside Omnes Capital in September 2022

Series B Details

Round type: Series B
Funding amount: $26,000,000
Currency: USD
Funding date: October 5, 2026
Lead investor: AVP (Atlantic Vantage Point)
Investors: AVP (Atlantic Vantage Point), Omnes Capital, Debiopharm, Blast Club, Yaday Health

The investor list shows continuity from the company's earlier financing: Omnes Capital and Debiopharm both participated in the Series A and return in the Series B, joined by Blast Club and Yaday Health alongside lead investor AVP.

Why It Matters for TechBio

The economics of gene, cell, RNA and DNA therapy development are dominated by the cost and time of experimental iteration. A platform that ranks candidate designs in silico before wet-lab work begins targets that bottleneck directly, from target discovery through vector and payload design and genotoxicity assessment.

For strategic acquirers and investors watching the TechBio landscape, WhiteLab Genomics combines three attributes worth tracking:

A defined computational wedge: predictive models applied to therapy design rather than general-purpose biology tooling.
A cross-border customer base: biotech and pharma customers in both Europe and the US.
Investor continuity: backing from Debiopharm and Omnes Capital across rounds, with AVP now leading.

What to Watch

With $26 million in new capital and a lead investor in AVP, the next markers for WhiteLab Genomics are the pace at which its in-silico platform is adopted across additional therapy modalities and how its North American sites scale alongside its Paris base. The company's Y Combinator Winter 2022 pedigree and its 2019 founding give it a multi-year track record heading into this round.